Inventaire - twoi znajomi i społeczności to twoja najlepsza biblioteka - Inventaire

Molecular mechanisms of cisplatin resistance

autor

Laura Senovilla

Guido Kroemer

Lorenzo Galluzzi

Oliver Kepp

Isabelle Martins

Ilio Vitale

Maria Castedo

opublikowano w: Oncogene

data publikacji: 2011-09-05

język: język angielski

główny temat: cisplatyna

Cites articles 161

Data

Tytuł

Autorzy

2011-01-07

Mitochondrial liaisons of p53.

Oliver Kepp, Lorenzo Galluzzi, Guido Kroemer, Ilio Vitale, Marcello Pinti, Eugenia Morselli
2011-06-29

Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors
2011-03-01

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, Mickaël Michaud, Oliver Kepp, Isabelle Martins, Sandy Adjemian, Laurie Menger, Abdul Qader Sukkurwala, Frédéric Schlemmer
2011-07-14

A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells

Edson Lucas dos Santos
2011-04-29

Mitotic catastrophe: a mechanism for avoiding genomic instability.

Lorenzo Galluzzi, Guido Kroemer, Ilio Vitale, Maria Castedo
2011-01-04

Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma
2011-03-01

p62/SQSTM1 involved in cisplatin resistance in human ovarian cancer cells by clearing ubiquitinated proteins

Ye Xu
2010-09-14

Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy
2010-04-20

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype.

Jan Lubiński
2010-08-01

Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells
2010-06-01

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator
2010-12-17

The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas

Michael Meyer-Hermann
2010-09-23

Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance
2010-02-09

MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer.

Jean-Charles Soria, Thierry Le Chevalier
2010-10-22

Autophagy and the integrated stress response

Guido Kroemer
2010-12-13

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

Laurence Zitvogel, Guido Kroemer, Oliver Kepp, Isabelle Martins, Antoine Tesniere, Sandy Adjemian, Laurie Menger, Frédéric Schlemmer
2010-02-01

Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs
2010

Reversal of multidrug resitance by natural substances from plants

Olga Wesołowska, Judit Hohmann
2010-07-01

Role of the copper transporter, CTR1, in platinum-induced ototoxicity
2010-01-01

Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer
2010-02-01

Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy
2010-11-01

Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance

Michael M. Gottesman
2010-01-01

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer

David A Gillespie
2010-09-16

Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression
2010-11-18

Calpain activation through galectin-3 inhibition sensitizes prostate cancer cells to cisplatin treatment

Pratima Nangia-Makker
2010-01-01

c-Abl phosphorylation of ΔNp63α is critical for cell viability
2009-02-01

Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy

Valentina Monica, Marco Lo Iacono, Matteo Giaj-Levra, Silvia Saviozzi, Mauro Papotti, Giorgio Scagliotti, Marco Volante, Silvia Novello, Paolo Ceppi
2009-04-07

Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species
2009-03-16

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer

Frederick Roy MacKintosh
2009-09-20

Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells
2009-02-24

Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma

Anthony Charles Nichols, Leif W Ellisen, William H. Westra
2009-10-11

A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin

Artykuł - wd:Q37926477

Witaj w Inventaire

biblioteka twoich znajomych i społeczności

dowiedz się więcej

jesteś offline